Back to results
US 2023/0053631 A1Published application
Antibodies to lilrb2
AssigneeJounce Therapeutics, Inc.
InventorsHeather B. COHEN, Lauren Pepper MACKENZIE, Yasmin RAMSAY, Donald Raymond SHAFFER, Jeffrey Yan-Fei SMITH, Kristin Shanea O'MALLEY, Kevin Patrick GUAY
Life of this patent
Estimating the term…
Abstract
Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.
Claims30
An antibody that specifically binds to human LILRB2, wherein the antibody comprises the following complementarity determining regions (CDRs):
- (a) a CDR-H1 comprising the amino acid sequence of JY(J)2G(J)2 (SEQ ID NO:
- 171);
- (b) a CDR-H2 comprising the amino acid sequence of (J)2W(J)11KJ (SEQ ID NO:
- 172);
- (c) a CDR-H3 comprising the amino acid sequence of (J)2I(J)3TDYV(J)3 (SEQ ID NO:
- 173);
- (d) a CDR-L1 comprising the amino acid sequence of (J)8DLJ (SEQ ID NO:
- 174);
- (e) a CDR-L2 comprising the amino acid sequence of (J)7 (SEQ ID NO:
- 175);
- and
- (f) a CDR-L3 comprising the amino acid sequence of (J)3YJYPLJ (SEQ ID NO:
- 176),
- wherein each J is independently a naturally occurring amino acid.
11 more elements
17-49. (canceled)
51-66. (canceled)
77-96. (canceled)
Dependencies are inferred from the claim text.